202 related articles for article (PubMed ID: 22350014)
1. Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester.
Tang Z; Yuan S; Hu Y; Zhang H; Wu W; Zeng Z; Yang J; Yun J; Xu R; Huang P
J Bioenerg Biomembr; 2012 Feb; 44(1):117-25. PubMed ID: 22350014
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
3. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.
Ganapathy-Kanniappan S; Kunjithapatham R; Geschwind JF
Anticancer Res; 2013 Jan; 33(1):13-20. PubMed ID: 23267123
[TBL] [Abstract][Full Text] [Related]
4. Glyceraldehyde-3-phosphate dehydrogenase promotes cancer growth and metastasis through upregulation of SNAIL expression.
Liu K; Tang Z; Huang A; Chen P; Liu P; Yang J; Lu W; Liao J; Sun Y; Wen S; Hu Y; Huang P
Int J Oncol; 2017 Jan; 50(1):252-262. PubMed ID: 27878251
[TBL] [Abstract][Full Text] [Related]
5. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death.
Ganapathy-Kanniappan S; Geschwind JF; Kunjithapatham R; Buijs M; Vossen JA; Tchernyshyov I; Cole RN; Syed LH; Rao PP; Ota S; Vali M
Anticancer Res; 2009 Dec; 29(12):4909-18. PubMed ID: 20044597
[TBL] [Abstract][Full Text] [Related]
6. The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression.
Ho N; Morrison J; Silva A; Coomber BL
Biosci Rep; 2016 Jan; 36(1):e00299. PubMed ID: 26740252
[TBL] [Abstract][Full Text] [Related]
7. Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists.
Ganapathy-Kanniappan S; Kunjithapatham R; Torbenson MS; Rao PP; Carson KA; Buijs M; Vali M; Geschwind JF
Radiology; 2012 Mar; 262(3):834-45. PubMed ID: 22357885
[TBL] [Abstract][Full Text] [Related]
8. A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells.
Chen TC; Yu J; Nouri Nigjeh E; Wang W; Myint PT; Zandi E; Hofman FM; Schönthal AH
Cancer Lett; 2017 Aug; 400():161-174. PubMed ID: 28450161
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel glyceraldehyde-3-phosphate dehydrogenase inhibitor via docking-based virtual screening.
Li T; Tan X; Yang R; Miao Y; Zhang M; Xi Y; Guo R; Zheng M; Li B
Bioorg Chem; 2020 Mar; 96():103620. PubMed ID: 32028064
[TBL] [Abstract][Full Text] [Related]
10. Elevated GAPDH expression is associated with the proliferation and invasion of lung and esophageal squamous cell carcinomas.
Hao L; Zhou X; Liu S; Sun M; Song Y; Du S; Sun B; Guo C; Gong L; Hu J; Guan H; Shao S
Proteomics; 2015 Sep; 15(17):3087-100. PubMed ID: 25944651
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of chemotherapeutic agents in glyceraldehyde-3-phosphate dehydrogenase-depleted human lung carcinoma A549 cells with the accelerated senescence phenotype.
Phadke M; Krynetskaia N; Krynetskiy E
Anticancer Drugs; 2013 Apr; 24(4):366-74. PubMed ID: 23377192
[TBL] [Abstract][Full Text] [Related]
12. 3-bromopyruvate inhibits glycolysis, depletes cellular glutathione, and compromises the viability of cultured primary rat astrocytes.
Ehrke E; Arend C; Dringen R
J Neurosci Res; 2015 Jul; 93(7):1138-46. PubMed ID: 25196479
[TBL] [Abstract][Full Text] [Related]
13. CARM1 Methylates GAPDH to Regulate Glucose Metabolism and Is Suppressed in Liver Cancer.
Zhong XY; Yuan XM; Xu YY; Yin M; Yan WW; Zou SW; Wei LM; Lu HJ; Wang YP; Lei QY
Cell Rep; 2018 Sep; 24(12):3207-3223. PubMed ID: 30232003
[TBL] [Abstract][Full Text] [Related]
14. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate.
Chen Z; Zhang H; Lu W; Huang P
Biochim Biophys Acta; 2009 May; 1787(5):553-60. PubMed ID: 19285479
[TBL] [Abstract][Full Text] [Related]
15. Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target.
Krasnov GS; Dmitriev AA; Snezhkina AV; Kudryavtseva AV
Expert Opin Ther Targets; 2013 Jun; 17(6):681-93. PubMed ID: 23445303
[TBL] [Abstract][Full Text] [Related]
16. 5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells.
McKenzie SM; Doe WF; Buffinton GD
Gut; 1999 Feb; 44(2):180-5. PubMed ID: 9895376
[TBL] [Abstract][Full Text] [Related]
17. Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent.
Dell'Antone P
Med Chem; 2009 Nov; 5(6):491-6. PubMed ID: 19534685
[TBL] [Abstract][Full Text] [Related]
18. Deregulation of glyceraldehyde-3-phosphate dehydrogenase expression during tumor progression of human cutaneous melanoma.
Ramos D; Pellín-Carcelén A; Agustí J; Murgui A; Jordá E; Pellín A; Monteagudo C
Anticancer Res; 2015 Jan; 35(1):439-44. PubMed ID: 25550585
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.
Nakano A; Miki H; Nakamura S; Harada T; Oda A; Amou H; Fujii S; Kagawa K; Takeuchi K; Ozaki S; Matsumoto T; Abe M
J Bioenerg Biomembr; 2012 Feb; 44(1):31-8. PubMed ID: 22298254
[TBL] [Abstract][Full Text] [Related]
20. C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia.
Ryland LK; Doshi UA; Shanmugavelandy SS; Fox TE; Aliaga C; Broeg K; Baab KT; Young M; Khan O; Haakenson JK; Jarbadan NR; Liao J; Wang HG; Feith DJ; Loughran TP; Liu X; Kester M
PLoS One; 2013; 8(12):e84648. PubMed ID: 24367685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
